Select Studies Reporting SSTR and 18F-FDG PET Imaging by Ki-67
| Study | Total no. patients (N) | N: Ki-67 or rate of growth | Tumor primary site | Indication for imaging | SSTR imaging type | SSTR imaging results | 18F-FDG PET imaging results |
| Belcohine et al. 2002 (19) | 17 | 15: Ki-67 ≤ 10% | GEP, lung, GU, thymus | Detection of mets | 111In | Positive in 10 of 15 (67%) | Positive in 8 of 15 (53%) |
| 1: Ki-67 ≥ 20% | Positive in 1 of 1 (100%) | Positive in 1 of 1 (100%) | |||||
| 1: undetermined | |||||||
| Kayani et al. 2008 (16) | 38 (25 with histology) | 13: Ki-67 ≤ 2% | GEP, lung, unknown | Suspected recurrence, primary tumor, mets | 68Ga | Positive and predominant uptake in 13 of 13 (100%) | Positive in 7 of 13 (54%) |
| 6: Ki-67 ≤ 5%–15% | Positive in 5 of 6 (83%), predominant uptake in 3 of 6 (50%) | Positive in 5 of 6 (83%) | |||||
| 6: Ki-67 ≥ 20% | Positive in 4 of 6 (67%) | Positive in 6 of 6 (100%) | |||||
| Adams et al. 1998 (20) | 20 | 4: Ki-67 low (no % reported) | GEP, MTC, thymic carcinoma | Primary tumor or LN mets | 111In | Positive in 4 of 4 (100%) | Positive in 0 of 4 (0%) |
| 16: Ki-67 high | Positive in 0 of 16 (0%) | Positive in 16 of 16 (100%) | |||||
| Pasquali et al. 1998 (21) | 16 | 8: slow-growing based on serial imaging | GEP, lung | Primary tumor or mets | 111In | Positive in 4 of 6 (67%) | Weakly positive in 1 of 8 (13%) |
| 8: fast-growing based on serial imaging | Positive in 8 of 8 (100%) | Positive in 8 of 8 (100%) | |||||
| Failed to detect primary in 3 of 11 | Mets detected in 5 of 6 | ||||||
| Binderup et al. 2010 (22) | 98 (88 with Ki-67) | 47: Ki-67 ≤ 2% | GEP, lung | Study prognostication | Not performed | Not performed | Positive in 19 of 47 (40%) |
| 27: Ki-67 > 2 ≤ 15% | Positive in 19 of 27 (70%) | ||||||
| 14: Ki-67 ≥ 15% | Positive in 13 of 14 (93%) | ||||||
| Has Simsek et al. 2014 (25) | 27 | 10: Ki-67 ≤ 2% | GEP | Primary tumor, staging | 68Ga | Positive and predominant in 10 of 10 (100%) | Low to mild uptake in 2 of 10 (20%) |
| 15: Ki-67 > 2 ≤ 20% | Positive in 12 of 15 and predominant in 11 of 15 (73%) | Significant uptake in 7 of 15 (47%) | |||||
| 2: Ki-67 ≥ 20% | Positive and predominant in 1 of 2 (50%) | Significant uptake in 2 of 2 (100%) |
Diff = differentiation; GEP = gastroenteropancreatic; GU = genitourinary; mets = metastases; MTC = medullary thyroid carcinoma; LN = lymph node.